08:30 AM EDT, 09/22/2025 (MT Newswires) -- MediciNova ( MNOV ) said Monday that it has completed patient enrollment for its phase 2b/3 trial evaluating ibudilast or MN-166 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease affecting nerves and spinal cord.

The study included 234 patients who were randomly assigned to one of two treatment arms at multiple clinical sites across the US and Canada, the company said.

The company said topline data are expected by the end of next year.

Shares of the company were down 1.6% in recent Monday premarket activity.